CN102362949A - Medicine for treating chronic pelvic inflammation and preparation method thereof - Google Patents
Medicine for treating chronic pelvic inflammation and preparation method thereof Download PDFInfo
- Publication number
- CN102362949A CN102362949A CN2011101073538A CN201110107353A CN102362949A CN 102362949 A CN102362949 A CN 102362949A CN 2011101073538 A CN2011101073538 A CN 2011101073538A CN 201110107353 A CN201110107353 A CN 201110107353A CN 102362949 A CN102362949 A CN 102362949A
- Authority
- CN
- China
- Prior art keywords
- effective site
- radix astragali
- rhizoma
- effective
- rhizoma corydalis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention which belongs to the technical field of medicines concretely discloses a medicine for treating chronic pelvic inflammation and a preparation method thereof. The medicine of the invention comprises the following raw materials, by weight, 16.5-33.0 parts of an effective extract of Smilax bockii Warb, 2.19-8.76 parts of an effective extract of Radix Astragali and 0.65-2.6 parts of an effective extract of Rhizoma Corydalis, wherein the effective extract of Smilax bockii Warb comprises total flavonoids and total saponins of Smilax bockii Warb, the effective extract of Radix Astragali is Astragaloside IV, and the effective extract of Rhizoma Corydalis comprises total alkaloids of Rhizoma Corydalis. The preparation of the effective extract of Smilax bockii Warb, the preparation of the effective extract of Radix Astragali, the preparation of the effective extract of Rhizoma Corydalis, and the mixing of the three effective extracts are carried out in the invention to prepare a tablet, a granule, a pill or a capsule. Smilax bockii Warb, Radix Astragali and Rhizoma Corydalis which are selected in the invention have obvious antiinflammatory effects, and the three medicines show a synergistic effect, so the absorption effect is better after purifying through the method of the invention, thereby the treatment effect of the medicine of the invention is better.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of medicine of treating chronic pelvic inflammatory disease and preparation method thereof.
Background technology
Chronic pelvic inflammatory disease is a common gynecological disease, sick in many ways, and it is relatively poor that common pelvic inflammatory disease is failed thoroughly treatment or patient's body constitution, due to the passing of time disease prolongs.The primary disease state of an illness is obstinate, and touching difficulty heals, even the influence fertility, brings very big misery to the patient.Because the chronic pelvic inflammatory disease cause of disease is complicated, diseased region is special, pathogenic bacteria produces the drug resistance characteristics, Western medicine shows weak curative effect or instability, side effect and takes greatly, for a long time and can cause cumulative action and produce its complication aspect treatment.And existing Chinese herbal medicine, though aspects such as its treatment inflammation absorption, healing of focus and prevention are superior to Western medicine, its course of treatment is long, medicine suffering clothes, and the patient often is difficult to adhere to and affects the treatment.
Summary of the invention
In order to address the above problem, the object of the present invention is to provide chronic medicine of a kind of better efficacy and preparation method thereof.
For realizing the foregoing invention purpose, technical scheme that the present invention adopts is following:
A kind of medicine of treating chronic pelvic inflammatory disease is characterized in that, its raw material weight umber ratio is:
16.5～33.0 parts of Rhizoma Smilacis Bockii effective sites, 2.19～8.76 parts of Radix Astragali effective sites, 0.65～2.6 part of Rhizoma Corydalis effective site; Said Rhizoma Smilacis Bockii effective site is Rhizoma Smilacis Bockii total flavones and total saponins, and said Radix Astragali effective site is astragaloside, and said Rhizoma Corydalis effective site is Rhizoma Corydalis total alkaloids.
Preferably, in the medicine of said treatment chronic pelvic inflammatory disease, its raw material weight umber ratio is:
24.75 parts of Rhizoma Smilacis Bockii effective sites, 4.38 parts of Radix Astragali effective sites, 1.3 parts of Rhizoma Corydalis effective sites.
A kind of method for preparing of said chronic pelvic inflammatory disease medicine comprises the step of producing and above-mentioned three kinds of effective sites are mixed and made into tablet, granule, pill or capsule of the producing of the producing of Rhizoma Smilacis Bockii effective site, Radix Astragali effective site, Rhizoma Corydalis effective site;
Said Rhizoma Smilacis Bockii effective site, Radix Astragali effective site and Rhizoma Corydalis effective site to produce step following:
With Rhizoma Smilacis Bockii, the Radix Astragali or the Rhizoma Corydalis after pulverizing, carry out reflux, extract, and filtration through alcohol-water solution, must filtrate;
Said filtrating is concentrated and remove alcohol, get concentrated solution;
Behind the capable polyamide column of said concentrated solution or macroporous resin column or gel chromatographic columns, with the alcohol-water solution eluting collect eluent;
Said eluent concentrate drying is got its effective site.
Preferably, in the method for preparing of said chronic pelvic inflammatory disease medicine, said Rhizoma Smilacis Bockii effective site produce step, specifically:
Get the Rhizoma Smilacis Bockii pulverizing medicinal materials and become coarse powder, the alcohol reflux twice of employing 60% adds 12 times of amount solvent extraction 2h for the first time, adds 10 times of amount solvent extraction 1.5h for the second time, and merge extractive liquid, filters to such an extent that filtrate;
Filtrate recycling ethanol is not distinguished the flavor of to there being alcohol, and be prepared into the medicinal liquid that concentration is 0.2g/ml;
Is the macroporous adsorptive resins of AB-8 with Rhizoma Smilacis Bockii medical material 5/9 heavy dried resin and concentrated solution with model on the speed of 2BV/h; The post bed of resin gets diameter and is 1: 6 at high proportion, becomes colourless to eluent, the flow velocity drip washing 6BV of reuse 20% ethanol 1.5-2BV/h with distilled water with the flow velocity eluting 6BV of 1.5-2BV/h; Discard; Flow velocity eluting 5BV with 70% ethanol 1.5-2BV/h collects 70% alcohol eluen, reclaims ethanol;
Under 70 ℃, eluent density is concentrated into 1.00-1.10; Again into and out of the air port temperature be respectively 150-190 ℃ with 80-95 ℃, nebulizer rotating speed 40MHz, peristaltic pump sample introduction speed 10-20Hz, cyclonic separation pressure reduction 0.6MPa condition under spray drying promptly get Rhizoma Smilacis Bockii effective site, yield must not be less than 1.0%.
Preferably, in the method for preparing of said chronic pelvic inflammatory disease medicine, said Radix Astragali effective site produce step, specifically:
Get the Milkvetch Root decoction pieces, employing water reflux, extract, twice adds 10 times of amount solvent extraction 2h for the first time, adds 8 times of amount solvent extraction 1.5h for the second time, and merge extractive liquid, filters to such an extent that filtrate;
Said filtrate recycling ethanol is not distinguished the flavor of to there being alcohol, and be prepared into the medicinal liquid that concentration is 0.2g/ml;
Is the macroporous adsorptive resins of AB-8 with Milkvetch Root 5/8 heavy dried resin and concentrated solution with model on the flow velocity of 1BV/h, and the post bed of resin gets diameter and is 1: 6 at high proportion; Washing 3BV, flow velocity 2BV/h is with 70% ethanol elution 3BV; Flow velocity 2BV/h collects 70% alcohol eluen, reclaims ethanol;
Under 70 ℃, eluent density is concentrated into 1.00-1.10; Again into and out of the air port temperature be respectively 150-170 ℃ with 80-95 ℃, nebulizer rotating speed 40MHz, peristaltic pump sample introduction speed 10-20Hz, cyclonic separation pressure reduction 0.6MPa condition under spray drying; Promptly get Radix Astragali effective site, yield must not be less than 1.0%.
Preferably, in the method for preparing of said chronic pelvic inflammatory disease medicine, said Rhizoma Corydalis effective site produce step, specifically:
Get corydalis tuber medicinal material and be ground into coarse powder, the alcohol reflux twice of employing 60% adds 6 times of amount solvent extraction 2h for the first time, adds 4 times of amount solvent extraction 1.5h for the second time, and merge extractive liquid, filters to such an extent that filtrate;
Said filtrate recycling ethanol is not distinguished the flavor of to there being alcohol, and be prepared into the concentrated solution that concentration is 0.4g/ml;
Is the macroporous adsorptive resins of AB-8 with corydalis tuber medicinal material 1/4 heavy dried resin and concentrated solution with model on the flow velocity of 2BV/h, and the post bed of resin gets diameter and is 1: 6 at high proportion, with distilled water eluting 6BV; Flow velocity is 2-3BV/h, and reuse 10% ethanol drip washing 2BV discards, and flow velocity is 2-3BV/h; 70% ethanol elution 5BV; Flow velocity is 2-3BV/h, collects 70% alcohol eluen, reclaims ethanol;
Under 70 ℃, eluent density is concentrated into 0.90-1.05; Again into and out of the air port temperature be respectively 150-190 ℃ with 80-95 ℃, nebulizer rotating speed 40MHz, peristaltic pump sample introduction speed 10-20Hz, cyclonic separation pressure reduction 0.6MPa condition under spray drying; Promptly get Rhizoma Corydalis effective site, yield must not be less than 0.03%.
The Rhizoma Smilacis Bockii that the present invention selects for use, Rhizoma Corydalis and the Radix Astragali all have tangible antiinflammatory action; Three kinds of medicines show synergism each other in addition; And through can making behind the inventive method purification that its assimilation effect is better, and then make that the therapeutic effect of medicine of the present invention is better.
The specific embodiment
Specify the present invention with the practical implementation method below, be used for explaining the present invention in schematic enforcement of the present invention and explanation, but not as to qualification of the present invention.
Embodiment 1:
Present embodiment discloses a kind of medicine and capsular method for preparing thereof of treating pelvic inflammatory disease.
Wherein, its raw material weight of this medicine is such as following:
Rhizoma Smilacis Bockii effective site 24.75 grams, Radix Astragali effective site 4.38 grams, Rhizoma Corydalis effective site 1.3 grams.
Its capsular method for preparing comprises the steps:
(1) be respectively 2.75%, 0.65% and 2.19% according to the average receipts cream rate behind Rhizoma Smilacis Bockii, Rhizoma Corydalis and the Radix Astragali effective site purification, correspondence takes by weighing each crude drug: Rhizoma Smilacis Bockii 900g, and Rhizoma Corydalis 200g, Radix Astragali 200g is subsequent use;
(2) producing of Rhizoma Smilacis Bockii effective site:
Get the Rhizoma Smilacis Bockii pulverizing medicinal materials and become coarse powder, the alcohol reflux twice of employing 60% adds 12 times of amount solvent extraction 2h for the first time, adds 10 times of amount solvent extraction 1.5h for the second time, and merge extractive liquid, filters to such an extent that filtrate;
Filtrate recycling ethanol is not distinguished the flavor of to there being alcohol, and be prepared into the medicinal liquid that concentration is 0.2g/ml;
Is the macroporous adsorptive resins of AB-8 with Rhizoma Smilacis Bockii medical material 5/9 heavy dried resin and concentrated solution with model on the speed of 2BV/h; The post bed of resin gets diameter and is 1: 6 at high proportion, becomes colourless to eluent, the flow velocity drip washing 6BV of reuse 20% ethanol 1.5-2BV/h with distilled water with the flow velocity eluting 6BV of 1.5-2BV/h; Discard; Flow velocity eluting 5BV with 70% ethanol 1.5-2BV/h collects 70% alcohol eluen, reclaims ethanol;
Under 70 ℃, eluent density is concentrated into 1.00-1.10; Again into and out of the air port temperature be respectively 150-190 ℃ with 80-95 ℃, nebulizer rotating speed 40MHz, peristaltic pump sample introduction speed 10-20Hz, cyclonic separation pressure reduction 0.6MPa condition under spray drying promptly get Rhizoma Smilacis Bockii effective site, yield must not be less than 1.0%.
(3) producing of Radix Astragali effective site:
Get the Milkvetch Root decoction pieces, employing water reflux, extract, twice adds 10 times of amount solvent extraction 2h for the first time, adds 8 times of amount solvent extraction 1.5h for the second time, and merge extractive liquid, filters to such an extent that filtrate;
Said filtrate recycling ethanol is not distinguished the flavor of to there being alcohol, and be prepared into the medicinal liquid that concentration is 0.2g/ml;
Is the macroporous adsorptive resins of AB-8 with Milkvetch Root 5/8 heavy dried resin and concentrated solution with model on the flow velocity of 1BV/h, and the post bed of resin gets diameter and is 1: 6 at high proportion; Washing 3BV, flow velocity 2BV/h is with 70% ethanol elution 3BV; Flow velocity 2BV/h collects 70% alcohol eluen, reclaims ethanol;
Under 70 ℃, eluent density is concentrated into 1.00-1.10; Again into and out of the air port temperature be respectively 150-170 ℃ with 80-95 ℃, nebulizer rotating speed 40MHz, peristaltic pump sample introduction speed 10-20Hz, cyclonic separation pressure reduction 0.6MPa condition under spray drying; Promptly get Radix Astragali effective site, yield must not be less than 1.0%.
(4) producing of Rhizoma Corydalis effective site:
Get corydalis tuber medicinal material and be ground into coarse powder, the alcohol reflux twice of employing 60% adds 6 times of amount solvent extraction 2h for the first time, adds 4 times of amount solvent extraction 1.5h for the second time, and merge extractive liquid, filters to such an extent that filtrate;
Said filtrate recycling ethanol is not distinguished the flavor of to there being alcohol, and be prepared into the concentrated solution that concentration is 0.4g/ml;
Is the macroporous adsorptive resins of AB-8 with corydalis tuber medicinal material 1/4 heavy dried resin and concentrated solution with model on the flow velocity of 2BV/h, and the post bed of resin gets diameter and is 1: 6 at high proportion, with distilled water eluting 6BV; Flow velocity is 2-3BV/h, and reuse 10% ethanol drip washing 2BV discards, and flow velocity is 2-3BV/h; 70% ethanol elution 5BV; Flow velocity is 2-3BV/h, collects 70% alcohol eluen, reclaims ethanol;
Under 70 ℃, eluent density is concentrated into 0.90-1.05; Again into and out of the air port temperature be respectively 150-190 ℃ with 80-95 ℃, nebulizer rotating speed 40MHz, peristaltic pump sample introduction speed 10-20Hz, cyclonic separation pressure reduction 0.6MPa condition under spray drying; Promptly get Rhizoma Corydalis effective site, yield must not be less than 0.03%.
(5) dry powder with step (2), (3), (4) merges, and mixing adds appropriate amount of starch, dextrin, microcrystalline Cellulose and carboxymethyl starch sodium and magnesium stearate, processes 1000 of finished products, every 0.4g, and packing promptly gets.
Need to prove that wherein used ethanol can also be used methanol, propanol, butanols, ethylene glycol, carbochain, and less than replacements such as 32 enols and phenol, these all are protection scope of the present invention less than 32 alkanols, carbochain.
Need to prove that wherein the big pore resin comprises nonpolar, low pole, Semi-polarity, polar homemade or import macroporous adsorbent resin, these all are protection scope of the present invention.
Embodiment 2:
Present embodiment discloses a kind of method for preparing of treating the medicine and the granule thereof of pelvic inflammatory disease.Being of this enforcement with the different of embodiment 1: its material rate, with and preparation method thereof (1) with (5) step.
Wherein, its raw material weight is such as following:
Rhizoma Smilacis Bockii effective site 16.5 grams, Radix Astragali effective site 2.19 grams, Rhizoma Corydalis effective site 0.65 gram.
Wherein, (1) and (5) of its process for producing granula goes on foot, and is specific as follows:
(1) be respectively 2.75%, 0.65% and 2.19% according to the average receipts cream rate behind Rhizoma Smilacis Bockii, Rhizoma Corydalis and the Radix Astragali effective site purification, correspondence takes by weighing each crude drug: Rhizoma Smilacis Bockii 600g, and Rhizoma Corydalis 100g, Radix Astragali 100g is subsequent use;
(5) dry powder with step (2), (3), (4) merges, and mixing adds appropriate amount of starch and Icing Sugar, and an amount of alcoholic solution of spray people is granulated, drying, and the dress pouch, every bag of 10g gets product 300 bags.
Embodiment 3:
Present embodiment discloses a kind of method for preparing of treating the medicine and the tablet thereof of pelvic inflammatory disease.Being of this enforcement with the different of embodiment 1: its material rate, with and preparation method thereof (1) with (5) step.
Wherein, its raw material weight is such as following:
Rhizoma Smilacis Bockii effective site 33 grams, Radix Astragali effective site 8.76 grams, Rhizoma Corydalis effective site 2.6 grams.
Wherein, (1) and (5) of its method for preparing tablet thereof goes on foot, and is specific as follows:
(1) be respectively 2.75%, 0.65% and 2.19% according to the average receipts cream rate behind Rhizoma Smilacis Bockii, Rhizoma Corydalis and the Radix Astragali effective site purification, correspondence takes by weighing each crude drug: Rhizoma Smilacis Bockii 1200g, and Rhizoma Corydalis 400g, Radix Astragali 400g is subsequent use;
(5) the effective site dry powder with step (2), (3), (4) merges, and mixing adds an amount of conventional pharmaceutic adjuvant, granulates, and tabletting just has been prepared into the tablet of medicine of the present invention, and every heavy 0.4g processes 1250 of finished products, and packing promptly gets.
Embodiment 4:
Present embodiment discloses a kind of method for preparing of treating the medicine and the tablet thereof of pelvic inflammatory disease.Being of this enforcement with the different of embodiment 1: its material rate, with and preparation method thereof (1) with (5) step.
Wherein, its raw material weight is such as following:
Rhizoma Smilacis Bockii effective site 19.25 grams, Radix Astragali effective site 3.285 grams, Rhizoma Corydalis effective site 0.975 gram.
Wherein, (1) and (5) of its method for preparing tablet thereof goes on foot, and is specific as follows:
(1) be respectively 2.75%, 0.65% and 2.19% according to the average receipts cream rate behind Rhizoma Smilacis Bockii, Rhizoma Corydalis and the Radix Astragali effective site purification, correspondence takes by weighing each crude drug: Rhizoma Smilacis Bockii 700g, Rhizoma Corydalis 150g, Radix Astragali 150g;
(5) the effective site dry powder with step (2), (3), (4) merges, and mixing adds an amount of conventional pharmaceutic adjuvant, granulates, and tabletting just has been prepared into the tablet of medicine of the present invention, and every heavy 0.4g processes 1250 of finished products, and packing promptly gets.
Embodiment 5:
Present embodiment discloses a kind of method for preparing of treating the medicine and the tablet thereof of pelvic inflammatory disease.Being of this enforcement with the different of embodiment 1: its material rate, with and preparation method thereof (1) with (5) step.
Wherein, its raw material weight is such as following:
Rhizoma Smilacis Bockii effective site 27.5 grams, Radix Astragali effective site 5.475 grams, Rhizoma Corydalis effective site 1.625 grams.
Wherein, (1) and (5) of its method for preparing tablet thereof goes on foot, and is specific as follows:
(1) be respectively 2.75%, 0.65% and 2.19% according to the average receipts cream rate behind Rhizoma Smilacis Bockii, Rhizoma Corydalis and the Radix Astragali effective site purification, correspondence takes by weighing each crude drug: Rhizoma Smilacis Bockii 1000g, Rhizoma Corydalis 250g, Radix Astragali 250g;
(5) the effective site dry powder with step (2), (3), (4) merges, and mixing adds an amount of conventional pharmaceutic adjuvant, granulates, and tabletting just has been prepared into the tablet of medicine of the present invention, and every heavy 0.4g processes 1250 of finished products, and packing promptly gets.
Embodiment 6:
Present embodiment discloses a kind of method for preparing of treating the medicine and the tablet thereof of pelvic inflammatory disease.Being of this enforcement with the different of embodiment 1: its material rate, with and preparation method thereof (1) with (5) step.
Wherein, its raw material weight is such as following:
Rhizoma Smilacis Bockii effective site 19.25 grams, Radix Astragali effective site 5.475 grams, Rhizoma Corydalis effective site 0.975 gram.
Wherein, (1) and (5) of its method for preparing tablet thereof goes on foot, and is specific as follows:
(1) be respectively 2.75%, 0.65% and 2.19% according to the average receipts cream rate behind Rhizoma Smilacis Bockii, Rhizoma Corydalis and the Radix Astragali effective site purification, correspondence takes by weighing each crude drug: Rhizoma Smilacis Bockii 700g, Rhizoma Corydalis 150g, Radix Astragali 250g;
(5) the effective site dry powder with step (2), (3), (4) merges, and mixing adds an amount of conventional pharmaceutic adjuvant, granulates, and tabletting just has been prepared into the tablet of medicine of the present invention, and every heavy 0.4g processes 1250 of finished products, and packing promptly gets.
Through the present invention the influence of the swollen model of rat granuloma is further specified the present invention below:
1, tried thing
Compositions 1: be the compositions of embodiment 1 preparation, know that by its proportioning raw materials the ratio of Rhizoma Smilacis Bockii, Rhizoma Corydalis and the Radix Astragali is 9: 2: 2.
Compositions 2: be the compositions of embodiment 2 preparations, know that by its proportioning raw materials the ratio of Rhizoma Smilacis Bockii, Rhizoma Corydalis and the Radix Astragali is 6: 1: 1.
Compositions 3: be the compositions of embodiment 3 preparations, know that by its proportioning raw materials the ratio of Rhizoma Smilacis Bockii, Rhizoma Corydalis and the Radix Astragali is 3: 1: 1.
Compositions 4: be the compositions of embodiment 4 preparations, know that by its proportioning raw materials the ratio of Rhizoma Smilacis Bockii, Rhizoma Corydalis and the Radix Astragali is 7: 1.5: 1.5.
Compositions 5: be the compositions of embodiment 5 preparations, know that by its proportioning raw materials the ratio of Rhizoma Smilacis Bockii, Rhizoma Corydalis and the Radix Astragali is 4: 1: 1.
Compositions 6: be the compositions of embodiment 6 preparations, know that by its proportioning raw materials the ratio of Rhizoma Smilacis Bockii, Rhizoma Corydalis and the Radix Astragali is 7: 1.5: 2.5.
In compositions 1-6, add the medicinal liquid that 0.5%CMC-Na solution is mixed with desired concn, subsequent use.
Positive control drug: gynecological's FUKE QIANJIN PIAN: Zhuzhou Qianjin Pharmacy Co., Ltd, lot number: 200706044; Rhizoma Smilacis Bockii capsule: Hubei good fortune people Pharmaceutical Co., Ltd, lot number: 20070804; Penicillin, Huabei Pharmaceutic Co., Ltd produces, lot number: B0508004.
2, laboratory animal
The SD rat, male and female half and half, 150-170g.
3, experimental technique
Adopt lumbar injection pentobarbital sodium 40mg.kg-1 anesthetized rat; Earlier behind the brush iodine tincture reuse alcohol disinfecting; Cut the osculum about 1cm in rat abdomen; The cotton balls (each heavily about 20mg) of (autoclave sterilization again of weighing earlier) of will sterilizing is inserted subcutaneous, skin suture immediately, and sterilize with mycillin liquid 0.2ml.Began administration the same day in performing the operation, each group is pressed 15m1.kg-1 and is irritated stomach, successive administration 7d; 2h after the last administration opens former otch, and cotton balls is taken out together with connective tissue on every side in the lump; Reject fatty tissue, oven dry is weighed, and the amount that the amount of weighing is deducted former cotton balls draws granulation heavily.
4, experimental result
See table 1.The compositions that table 1 is got thing, the different proportionings with Radix Astragali extract of Rhizoma Corydalis extract for Rhizoma Smilacis Bockii is to the bullate result of influence of rat granuloma.
5, experiment brief summary
Know by granulation weight contrast in the table 1, give rats gavaged compositions 1-6, the swollen model of rat granuloma is all had tangible antiinflammatory action.
6, experiment conclusion
The compositions of Rhizoma Smilacis Bockii extract, Rhizoma Corydalis extract and Radix Astragali extract has tangible antiinflammatory action, and shows synergism, and three's weight ratio is:
Rhizoma Smilacis Bockii 60～120: the Radix Astragali 10～40: Rhizoma Corydalis 10～40.
Table 1
Annotate: compare * P＜0.05 with negative control group, * * P＜0.01; With the FUKE QIANJIN PIAN comparison Δ P of gynecological＜0.05, Δ Δ P＜0.01; Compare #P＜0.05, ##P＜0.01, ###P＜0.01 with the Rhizoma Smilacis Bockii capsule.
Need to prove that the present invention not only comprises tablet, granule, pill or capsule, can also be other oral solid formulations and slow control diluent, these all are protection scope of the present invention.
More than the technical scheme that the embodiment of the invention provided has been carried out detailed introduction; Used concrete example among this paper the principle and the embodiment of the embodiment of the invention are set forth, the explanation of above embodiment only is applicable to the principle that helps to understand the embodiment of the invention; Simultaneously, for one of ordinary skill in the art, according to the embodiment of the invention, the part that on the specific embodiment and range of application, all can change, in sum, this description should not be construed as limitation of the present invention.
Claims (6)
1. a medicine of treating chronic pelvic inflammatory disease is characterized in that, its raw material weight umber ratio is:
16.5～33.0 parts of Rhizoma Smilacis Bockii effective sites, 2.19～8.76 parts of Radix Astragali effective sites, 0.65～2.6 part of Rhizoma Corydalis effective site;
Said Rhizoma Smilacis Bockii effective site is Rhizoma Smilacis Bockii total flavones and total saponins, and said Radix Astragali effective site is astragaloside, and said Rhizoma Corydalis effective site is Rhizoma Corydalis total alkaloids.
2. the medicine of treatment chronic pelvic inflammatory disease according to claim 1 is characterized in that, its raw material weight umber ratio is:
24.75 parts of Rhizoma Smilacis Bockii effective sites, 4.38 parts of Radix Astragali effective sites, 1.3 parts of Rhizoma Corydalis effective sites.
3. the method for preparing of the said chronic pelvic inflammatory disease medicine of claim 1 is characterized in that:
The step of producing and above-mentioned three kinds of effective sites are mixed and made into tablet, granule, pill or capsule that comprises the producing of the producing of Rhizoma Smilacis Bockii effective site, Radix Astragali effective site, Rhizoma Corydalis effective site;
Said Rhizoma Smilacis Bockii effective site, Radix Astragali effective site and Rhizoma Corydalis effective site to produce step following:
With Rhizoma Smilacis Bockii, the Radix Astragali or the Rhizoma Corydalis after pulverizing, carry out reflux, extract, and filtration through alcohol-water solution, must filtrate;
Said filtrating is concentrated and remove alcohol, get concentrated solution;
Behind the capable polyamide column of said concentrated solution or macroporous resin column or gel chromatographic columns, with the alcohol-water solution eluting collect eluent;
Said eluent concentrate drying is got its effective site.
4. the method for preparing of chronic pelvic inflammatory disease medicine according to claim 3 is characterized in that:
Said Rhizoma Smilacis Bockii effective site produce step, specifically:
Get the Rhizoma Smilacis Bockii pulverizing medicinal materials and become coarse powder, the alcohol reflux twice of employing 60% adds 12 times of amount solvent extraction 2h for the first time, adds 10 times of amount solvent extraction 1.5h for the second time, and merge extractive liquid, filters to such an extent that filtrate;
Filtrate recycling ethanol is not distinguished the flavor of to there being alcohol, and be prepared into the medicinal liquid that concentration is 0.2g/ml;
Is the macroporous adsorptive resins of AB-8 with Rhizoma Smilacis Bockii medical material 5/9 heavy dried resin and concentrated solution with model on the speed of 2BV/h; The post bed of resin gets diameter and is 1: 6 at high proportion, becomes colourless to eluent, the flow velocity drip washing 6BV of reuse 20% ethanol 1.5-2BV/h with distilled water with the flow velocity eluting 6BV of 1.5-2BV/h; Discard; Flow velocity eluting 5BV with 70% ethanol 1.5-2BV/h collects 70% alcohol eluen, reclaims ethanol;
Under 70 ℃, eluent density is concentrated into 1.00-1.10; Again into and out of the air port temperature be respectively 150-190 ℃ with 80-95 ℃, nebulizer rotating speed 40MHz, peristaltic pump sample introduction speed 10-20Hz, cyclonic separation pressure reduction 0.6MPa condition under spray drying promptly get Rhizoma Smilacis Bockii effective site, yield must not be less than 1.0%.
5. the method for preparing of chronic pelvic inflammatory disease medicine according to claim 3 is characterized in that:
Said Radix Astragali effective site produce step, specifically:
Get the Milkvetch Root decoction pieces, employing water reflux, extract, twice adds 10 times of amount solvent extraction 2h for the first time, adds 8 times of amount solvent extraction 1.5h for the second time, and merge extractive liquid, filters to such an extent that filtrate;
Said filtrate recycling ethanol is not distinguished the flavor of to there being alcohol, and be prepared into the medicinal liquid that concentration is 0.2g/ml;
Is the macroporous adsorptive resins of AB-8 with Milkvetch Root 5/8 heavy dried resin and concentrated solution with model on the flow velocity of 1BV/h, and the post bed of resin gets diameter and is 1: 6 at high proportion; Washing 3BV, flow velocity 2BV/h is with 70% ethanol elution 3BV; Flow velocity 2BV/h collects 70% alcohol eluen, reclaims ethanol;
Under 70 ℃, eluent density is concentrated into 1.00-1.10; Again into and out of the air port temperature be respectively 150-170 ℃ with 80-95 ℃, nebulizer rotating speed 40MHz, peristaltic pump sample introduction speed 10-20Hz, cyclonic separation pressure reduction 0.6MPa condition under spray drying; Promptly get Radix Astragali effective site, yield must not be less than 1.0%.
6. the method for preparing of chronic pelvic inflammatory disease medicine according to claim 3 is characterized in that:
Said Rhizoma Corydalis effective site produce step, specifically:
Get corydalis tuber medicinal material and be ground into coarse powder, the alcohol reflux twice of employing 60% adds 6 times of amount solvent extraction 2h for the first time, adds 4 times of amount solvent extraction 1.5h for the second time, and merge extractive liquid, filters to such an extent that filtrate;
Said filtrate recycling ethanol is not distinguished the flavor of to there being alcohol, and be prepared into the concentrated solution that concentration is 0.4g/ml;
Is the macroporous adsorptive resins of AB-8 with corydalis tuber medicinal material 1/4 heavy dried resin and concentrated solution with model on the flow velocity of 2BV/h, and the post bed of resin gets diameter and is 1: 6 at high proportion, with distilled water eluting 6BV; Flow velocity is 2-3BV/h, and reuse 10% ethanol drip washing 2BV discards, and flow velocity is 2-3BV/h; 70% ethanol elution 5BV; Flow velocity is 2-3BV/h, collects 70% alcohol eluen, reclaims ethanol;
Under 70 ℃, eluent density is concentrated into 0.90-1.05; Again into and out of the air port temperature be respectively 150-190 ℃ with 80-95 ℃, nebulizer rotating speed 40MHz, peristaltic pump sample introduction speed 10-20Hz, cyclonic separation pressure reduction 0.6MPa condition under spray drying; Promptly get Rhizoma Corydalis effective site, yield must not be less than 0.03%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110107353.8A CN102362949B (en) | 2011-04-26 | 2011-04-26 | Medicine for treating chronic pelvic inflammation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110107353.8A CN102362949B (en) | 2011-04-26 | 2011-04-26 | Medicine for treating chronic pelvic inflammation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102362949A true CN102362949A (en) | 2012-02-29 |
| CN102362949B CN102362949B (en) | 2014-01-22 |
Family
ID=45689565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110107353.8A Active CN102362949B (en) | 2011-04-26 | 2011-04-26 | Medicine for treating chronic pelvic inflammation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102362949B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106492069A (en) * | 2016-12-09 | 2017-03-15 | 南方医科大学南方医院 | Prevent and treat effective ingredient in Chinese of chronic pelvic inflammatory disease and its preparation method and application |
| CN108434375A (en) * | 2018-06-29 | 2018-08-24 | 杭州光启医疗科技发展有限公司 | A kind of Chinese medicine composition and preparation method thereof for treating pelvic infecton |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101164576A (en) * | 2006-10-17 | 2008-04-23 | 臧育增 | Traditional Chinese medicine for treating woman pelvic inflammation and adnexa disease and its preparing technology |
-
2011
- 2011-04-26 CN CN201110107353.8A patent/CN102362949B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101164576A (en) * | 2006-10-17 | 2008-04-23 | 臧育增 | Traditional Chinese medicine for treating woman pelvic inflammation and adnexa disease and its preparing technology |
Non-Patent Citations (4)
| Title |
|---|
| 余世强等: "中医药治疗慢性盆腔炎概述", 《光明中医》, vol. 23, no. 11, 20 November 2008 (2008-11-20) * |
| 刘颖: "中医药治疗慢性盆腔炎研究进展", 《中国中医药信息杂志》, vol. 8, no. 10, 31 October 2001 (2001-10-31) * |
| 贾传弟: "抗慢性盆腔炎中药的实验研究进展", 《中医药临床杂志》, vol. 20, no. 02, 1 April 2008 (2008-04-01) * |
| 黄嗣航等: "菝葜治疗大鼠慢性盆腔炎有效部位的初步筛选", 《现代食品与药品杂志》, vol. 16, no. 02, 30 April 2006 (2006-04-30) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106492069A (en) * | 2016-12-09 | 2017-03-15 | 南方医科大学南方医院 | Prevent and treat effective ingredient in Chinese of chronic pelvic inflammatory disease and its preparation method and application |
| CN106492069B (en) * | 2016-12-09 | 2019-10-11 | 南方医科大学南方医院 | Chinese medicine composition and the application for preventing and treating chronic pelvic inflammatory disease |
| CN108434375A (en) * | 2018-06-29 | 2018-08-24 | 杭州光启医疗科技发展有限公司 | A kind of Chinese medicine composition and preparation method thereof for treating pelvic infecton |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102362949B (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102784284B (en) | Preparation method of sugar-free oral liquid with anti-cancer effect | |
| KR101088539B1 (en) | Chinese medicinal compositions for treating headache, formulations and processes for preparation therof | |
| CN104435226B (en) | Fevervine extract and application thereof | |
| CN112870236B (en) | Flavone effective part of abelmoschus manihot and preparation method and application thereof | |
| WO2012119560A1 (en) | Preparation method for extractive of jinxuan hemorrhoid washing powder botanicals | |
| CN102772500B (en) | Relingqing Polygonum capitatum Buch-Ham ex D.Don raw material extract with anti-inflammatory action | |
| CN101480484B (en) | Preparation method of radix sileris Tongsheng powder preparation | |
| CN101607049B (en) | Separation and concentration method of drug extract liquid for preparing hemorrhoid diminishing preparation | |
| CN102362949B (en) | Medicine for treating chronic pelvic inflammation and preparation method thereof | |
| CN101371882A (en) | Method for preparing Artemisia capillaris decoction formulation | |
| CN102342945A (en) | Application of Cortex Ilicis Rotundae saponin compound in preparing anti-inflammatory and analgetic medicament | |
| CN102357124B (en) | Chinese medicine combination with effects of detumescence and inflammatory resistance and preparation method thereof | |
| CN101693073B (en) | Compound caesalpinia pulcherrima spraying agent and preparation method thereof | |
| CN1985944A (en) | Chinese medicine composition for treating cutaneous pruritus, rubella and other diseases | |
| CN101919919B (en) | Fukean dispersible tablet and preparation method thereof | |
| CN102940747B (en) | Medicine composition for treating gout | |
| CN106581236A (en) | Medicinal composition for promoting gastric motility, and preparation method and application thereof | |
| CN106581109A (en) | Cerebral thrombosis treating pharmaceutical composition | |
| CN101518584A (en) | Traditional Chinese medicine for curing urinary system infection and preparation method thereof | |
| CN101850009B (en) | Jinwei calculus-eliminating preparation and preparation method thereof | |
| CN107638453B (en) | Fuyanting granules and preparation method thereof | |
| CN100475248C (en) | A medicine for treating metrorrhagia and preparation process thereof | |
| CN104043100A (en) | Use of slug protein in preparing medicines for treating asthma | |
| CN101167924B (en) | Method for producing traditional Chinese medicine preparation of six ingredients with rehmannia | |
| CN100450502C (en) | Active extract of lamtophlomis rotata and its preparing method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |